腺苷A2AR拮抗剂对中枢炎症性小胶质细胞形态和功能的影响

doi:10.12092/j.issn.1009-2501.2019.12.010

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (12): 1376-1384.doi: 10.12092/j.issn.1009-2501.2019.12.010

腺苷A2AR拮抗剂对中枢炎症性小胶质细胞形态和功能的影响

陈瑜¹，殷为勇²，陈艳艳²，朱振国²，郑荣远²，郑浏璞³

¹温州医科大学附属第一医院康复科, ²神经内科，³麻醉科，温州 325000，浙江

收稿日期:2019-03-27 修回日期:2019-11-15 出版日期:2019-12-26 发布日期:2020-01-07
通讯作者: 郑浏璞，女，硕士，主治医师、讲师，主要研究方向：器官与脑损伤保护机制及药物研究。 Tel:0577-55579095 E-mail:457087107@qq.com
作者简介:陈瑜，女，硕士，住院医师，主要研究方向：神经药理与神经免疫。 Tel:0577-88069320 E-mail: cherrywzmc@163.com
基金资助:
温州市科技局项目(Y20180740)；国家自然科学基金项目(81371321)

Effects of adenosine A2A receptor antagonist on lipopolysaccharide induced inflammatory BV-2 microglial cells' morphology and function

CHEN Yu ¹，YIN Weiyong²，CHEN Yanyan ²，ZHU Zhenguo ²，ZHENG Rongyuan ²，ZHENG Liupu³

¹ Department of Rehabilitation, the First Affiliated Hospital of Wenzhou Medical University; ²Department of Neurology；³Department of Anesthesiology, Wenzhou 325000, Zhejiang，China

Received:2019-03-27 Revised:2019-11-15 Online:2019-12-26 Published:2020-01-07

摘要/Abstract

摘要：

目的:探讨腺苷A2A受体拮抗剂对实验性自身免疫性脑脊髓炎（EAE）的治疗作用及其对中枢炎症性小胶质细胞形态和功能的影响。方法:MOG35-55免疫诱导建立EAE模型，EAE小鼠出现神经功能缺损症状后开始腹腔注射腺苷A2AR拮抗剂至发病后第10天。ELISA法检测中枢神经系统内IFN-γ、IL-17、TGF-β、IL-10的表达情况，免疫荧光双重染色法检测小胶质细胞内M1型细胞标志物诱导型一氧化氮合酶（iNOS）和M2型细胞标志物精氨酸酶I（ArgI）的合成情况。离体培养BV-2小胶质细胞，LPS诱导的小胶质细胞炎症反应，并予A2AR拮抗剂干预，Real-time PCR和ELISA法检测M1型和M2型细胞相关的细胞因子RNA表达水平和分泌水平。Western Blot法检测各组小胶质细胞内M1型和M2型细胞标志物的表达量。结果:腺苷A2AR拮抗剂能有效缓解发病后EAE小鼠的神经功能缺损症状，降低IFN-γ的分泌水平，使M1型细胞相关的iNOS合成减少，M2型细胞相关的ArgI合成增多。腺苷A2AR拮抗剂能减少LPS刺激后BV-2小胶质细胞M1型细胞相关的细胞因子IL-1β的mRNA表达量和分泌量，对M2型细胞相关的细胞因子及蛋白无显著影响。结论:腺苷A2AR拮抗剂对发病后的EAE小鼠有肯定的治疗作用，其机制可能与改变中枢炎症过程中小胶质细胞的表型（M1/M2转换）改变（形态和功能）有关。

关键词: 腺苷A2A受体, 实验性自身免疫性脑脊髓炎, 小胶质细胞, 受体拮抗剂

Abstract:

AIM: To investigate the therapeutic effects of adenosine A2A receptor antagonist on experimental autoimmune encephalomyelitis (EAE) and to explore the regulating effects on microglia morphology and function. METHODS: EAE model was induced by MOG35-55 in C57BL/6 mice. Adenosine A2AR antagonists were given by intraperitoneal injection as EAE mice showed neurobehavioral deficits. The treatment lasted ten days until EAE mice reached highest clinical score. ELISA method was used to detect the expression of pro-inflammatory cytokine in central nervous system; immunofluorescence double staining was used to detect M1 cell related markers and M2 cell related markers in microglia. In vitro, activated BV-2 microglia cell line was induced by lipopolysaccharide (LPS) and then was intervened by the A2AR antagonists. Real-time PCR and ELISA method were used to detect the M1 and M2 cells related cytokines. Western Blot method was used to detect the synthesis of M1 and M2 cell related markers. RESULTS:Adenosine A2AR antagonists can effectively ameliorate the EAE-induced neurobehavioral deficits when treated after onset of EAE, and can reduce the secretion of pro-inflammatory cytokine IFN-γ, and M1 cells related iNOS synthesis while increased M2 type cells related ArgI synthesis. Adenosine A2AR antagonists can reduce LPS-induced BV-2 M1 microglial cells related cytokines IL-1β, and had no influence on M2 cells related cytokines and protein. CONCLUSION: Adenosine A2AR antagonists have definite therapeutic effect on EAE mice when treated after the onset of EAE; its underlying mechanism may be involved with shift of phenotype (M1/M2) and changes in morphology and function of microglia during neuro-inflammatory process.

Key words: adenosine A2A receptor, experimental autoimmune encephalomyelitis, microglia, antagonist

中图分类号:

R965.2

陈瑜，殷为勇，陈艳艳，朱振国，郑荣远，郑浏璞. 腺苷A2AR拮抗剂对中枢炎症性小胶质细胞形态和功能的影响[J]. 中国临床药理学与治疗学, 2019, 24(12): 1376-1384.

CHEN Yu，YIN Weiyong，CHEN Yanyan，ZHU Zhenguo，ZHENG Rongyuan，ZHENG Liupu. Effects of adenosine A2A receptor antagonist on lipopolysaccharide induced inflammatory BV-2 microglial cells' morphology and function[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1376-1384.

参考文献

［1］Steinman L.Multiple sclerosis:a two-stage disease［J］.Nat immunol,2001,2(9):762-764.
［2］Neuhaus O,Archelos JJ,Hartung HP.Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection［J］.Trends Pharmacol Sci,2003,24(3):131-138.
［3］Lopez-Diego RS,Weiner HL.Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary［J］.Nat Rev Drug Discov,2008,7(11):909-925.
［4］Gordon S.Alternative activation of macrophages［J］.Nat Rev Immunol,2003,3(1):23-35.
［5］Liu C,Li Y,Yu J,et al.Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil［J］.PloS One,2013,8(2):e54841.
［6］Fredholm BB,IJzerman AP,Jacobson KA,et al.Nomenclature and classification of adenosine receptors--an update［J］.Pharmacol Rev,2011，63(1):1-34.
［7］Blackburn MR,Vance CO,Morschl E,et al.Adenosine receptors and inflammation［J］.Handb Exp Pharmacol,2009,(193):215-269.
［8］Schulte G,Fredholm BB.Signalling from adenosine receptors to mitogen-activated protein kinases［J］.Cell Signal,2003,15(9):813-827.
［9］Yao SQ,Li ZZ,Huang QY,et al.Genetic inactivation of the adenosine A2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis［J］.J Neurochem,2012,123(1):100-112.
［10］Mills JH,Kim DG,Krenz A,et al.A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis［J］.J Immunol,2012,188(11):5713-5722.
［11］Mills JH,Thompson LF,Mueller C,et al.CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis［J］.Proc Natl Acad Sci USA,2008,105(27):9325-9330.
［12］Wang T,Xi NN,Chen Y,et al.Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice:therapeutic window and receptor subtype mechanism［J］.Neuropharmacology,2014,86,203-211.
［13］Li F,Zhang ZX,Liu YF,et al.2-BFI ameliorates EAE-induced mouse spinal cord damage:effective therapeutic time window and possible mechanisms［J］.Brain Res,2012,1483:13-19.
［14］陈瑜，郑荣远，方恢林，等.实验性自身免疫性脑脊髓炎小鼠神经损害与脑组织中丝裂原活化蛋白激酶表达的关系［J］.中国临床神经科学,2014,22(2):126-134.
［15］Li Y,Liu L,Kang J,et al.Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression［J］.J Neurosci,2000,20(1):149-155.
［16］Mrak RE,Sheng JG,Griffin WS.Glial cytokines in Alzheimer's disease:review and pathogenic implications［J］.Hum Pathol,1995,26(8):816-823.
［17］Shaftel SS,Griffin WS,O'Banion MK.The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective［J］.J Neuroinflammation,2008,5:7.
［18］Simoes AP,Duarte JA,Agasse F,et al.Blockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway［J］.J Neuroinflammation,2012,9:204.
［19］Liu G,Ma H,Qiu L,et al.Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice［J］.Immunol Cell Biol,2011,89(1):130-142.
［20］Li HH,Zhao HZ,Neufeld EF,et al.Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B［J］.J Neurosci Res,2002,69(1):30-38.
［21］Gratchev A,Kzhyshkowska J,Utikal J,et al.Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages［J］.SScand J Immunol，2005,61(1):10-17.
［22］Kahnert A,Seiler P,Stein M,et al.Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis［J］.Eur J Immunol，2006，36(3):631-647.
［23］Kigerl KA,Gensel JC,Ankeny DP,et al.Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord［J］.J Neurosci，2009,29(43):13435-13444.
［24］Mikita J,Dubourdieu-Cassagno N,Deloire MS,et al.Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis.Amelioration of clinical status by M2 activated monocyte administration［J］.Mult Scler，2011,17(1):2-15.
［25］Saura J,Angulo E,Ejarque A,et al.Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia［J］.J Neurochem，2005,95(4):919-929.

[1]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[2]	程宽. 非奈利酮的研究应用新进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 450-456.
[3]	张静, 高丹阳, 于康, 林晓婉, 曹颖, 刘晓, 缪慧慧, 李天佐. 不同吸入麻醉药对新生期大鼠神经胶质细胞活化的影响[J]. 中国临床药理学与治疗学, 2022, 27(12): 1391-1399.
[4]	潘娅岚，苑文超，马勇，郭杨，郑苏阳，徐桂华，刘家欢. 脊髓康对大鼠脊髓损伤区小胶质细胞/神经元的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 151-158.
[5]	张睿，李冰洁，李庆林. 酸枣仁皂苷A对脂多糖诱导小胶质细胞活化的影响及神经保护作用[J]. 中国临床药理学与治疗学, 2018, 23(2): 126-131.
[6]	厉芳，郑浏璞，翁建龙，郭涛，宋兴伟，郑荣远. 咪唑克生减缓大鼠实验性自身免疫性脑脊髓炎脑损伤的保护作用时间窗研究[J]. 中国临床药理学与治疗学, 2018, 23(1): 1-7.
[7]	夏洪莲, 陈猛, 芦相玉, 胡春阳, 刘永梁, 张艳丽, 刘岩. 腺苷A1受体拮抗剂对异丙酚诱导脑缺血再灌注损伤大鼠细胞凋亡的影响[J]. 中国临床药理学与治疗学, 2015, 20(7): 727-731.
[8]	宫登辉, 郑卫红, 罗妮, 汤桂成. 从大鼠脊髓背角Iba1的表达探讨天麻素对化疗诱导神经病理性疼痛的作用及其机制[J]. 中国临床药理学与治疗学, 2014, 19(7): 743-746.
[9]	张银妆, 陈碧莲. 抗血小板膜P₂Y₁₂受体拮抗剂的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(7): 824-830.
[10]	赵恬, 顾亮, 杜坚宗, 钦光跃. 孟鲁司特治疗老年稳定期慢性阻塞性肺疾病患者的疗效分析[J]. 中国临床药理学与治疗学, 2013, 18(1): 66-70.
[11]	胡爱虹, 李小明, 马欢杰. H2受体拮抗剂应用与肺炎发生危险的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(5): 536-542.
[12]	韩素芳. 血管紧张素转换酶抑制剂联合血管紧张素II受体拮抗剂对糖尿病肾病肾功能临床疗效的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(11): 1257-1262.
[13]	林希, 杨帆, 吴斌, 张晓燕, 林春. 雷莫司琼降低幼鼠内脏痛觉敏感性[J]. 中国临床药理学与治疗学, 2012, 17(10): 1102-1107.
[14]	陈艾东, 李娟, 谢海棠. 内皮素心血管效应的研究进展[J]. 中国临床药理学与治疗学, 2011, 16(8): 937-944.
[15]	李晓倩, 柯永胜. 经皮冠状动脉介入治疗术中无复流现象防治研究进展[J]. 中国临床药理学与治疗学, 2011, 16(5): 595-600.

腺苷A2AR拮抗剂对中枢炎症性小胶质细胞形态和功能的影响

Effects of adenosine A2A receptor antagonist on lipopolysaccharide induced inflammatory BV-2 microglial cells' morphology and function

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价